Meeting
2023 ASCO Annual Meeting
ASC2ESCALATE: A US phase 2, single-arm, dose-escalation study of asciminib monotherapy in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) previously treated with 1 prior tyrosine kinase inhibitor (TKI).
Authors
Ehab L. Atallah
Medical College of Wisconsin, Milwaukee, WI
Ehab L. Atallah , Michael J. Mauro , Koji Sasaki , Moshe Y. Levy , Paul B. Koller , Islam Sadek , Daisy Yang , Julie Ruckel-Kumar , Mahmudul H Khan , Jorge E. Cortes
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant
Track
Hematologic Malignancies
Sub Track
Chronic Leukemia—CML
Clinical Trial Registration Number
NCT05384587
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr TPS7082)
DOI
10.1200/JCO.2023.41.16_suppl.TPS7082
Abstract #
TPS7082
Poster Bd #
207b
Abstract Disclosures
Similar Posters
Poster
2019 ASCO Annual Meeting
A multicenter, randomized phase III study of asciminib (ABL001) versus bosutinib in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) previously treated with ≥2 tyrosine kinase inhibitors (TKIs).
First Author: Michael J. Mauro
Poster
2018 ASCO Annual Meeting
Clinical development of asciminib (ABL001) in chronic myeloid leukemia (CML): A randomized phase 3 study vs. bosutinib.
First Author: Michael J. Mauro
Poster
2016 ASCO Annual Meeting
4-year results of the ponatinib phase II PACE trial in patients (pts) with heavily pretreated leukemia.
First Author: Jorge E. Cortes
Poster
2023 ASCO Annual Meeting
Report of a chronic myeloid leukemia registry in a low-and middle-income setting.
First Author: Nicolas Anthony Othieno-Abinya